NCT03075553 2020-04-21Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaMayo ClinicPhase 2 Terminated12 enrolled 13 charts
NCT02420873 2018-08-28An Open-label Phase II Study of Lorvotuzumab MertansineM.D. Anderson Cancer CenterPhase 2 Completed9 enrolled 7 charts